**Name of Journal: *World Journal of Clinical Cases***

**Manuscript NO: 42761**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Safety of fecal microbiota transplantation in chinese children: a single-center retrospective study**

Zhang XY *et al*. Safety of FMT in pediatric

Xin-Yue Zhang, Yi-Zhong Wang, Xiao-Lu Li, Hui Hu, Hai-Feng Liu, Dan Li, Yong-Mei Xiao, Ting Zhang

**Xin-Yue Zhang, Yi-Zhong Wang, Xiao-Lu Li, Hui Hu, Hai-Feng Liu, Dan Li, Yong-Mei Xiao, Ting Zhang,** Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai 200040, China

**ORCID number:** Xin-Yue Zhang (0000-0002-4821-9795); Yi-Zhong Wang (0000-0002-9390-8864); Xiao-Lu Li (0000-0003-3057-3320); Hui Hu (0000-0001-6544-3070); Hai-Feng Liu (0000-0002-5620-5000); Dan Li (0000-0002-5518-8421); Yong-Mei Xiao (0000-0002-1591-7490); Ting Zhang (0000-0001-9391-8926).

**Author contributions:** All authors helped to perform the research; Zhang XY contributed to writing manuscript, performing procedures and data analysis; Wang YZ contributed to manuscript writing, drafting conception and design and data analysis; Li XL contributed to writing the manuscript and collecting data; Hu H, Liu HF, Li D and Xiao YM contributed to patient recruitment, diagnosis and treatment; Zhang T contributed to writing the manuscript, study conception and design, cohort setting and patient management.

**Supported by** Shanghai Hospital Development Center New Frontier Technology Joint Research Project, No. SHDC12017115.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Shanghai Children’s Hospital (2014RY015-E02).

**Informed consent statement:** Written informed consent was obtained from parents or legal guardians of all pediatric subjects.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author to: Ting Zhang, PhD, Professor,** Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children’s Hospital, Shanghai Jiao Tong University, No. 355 of Luding Road, Shanghai 200062, China. [zhangt@shchildren.com.cn](mailto:zhangt@shchildren.com.cn)

**Telephone:** +86-21-52976338

**Fax:** +86-21-52976338

**Received:** October 15, 2018

**Peer-review started:** October 15, 2018

**First decision:** November 7, 2018

**Revised:** November 22, 2018

**Accepted:** November 30, 2018

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Fecal microbiota transplantation (FMT) is the administration of fecal bacteria liquid from healthy donors to a recipient’s digestive tract, which is recommended as a therapeutic method for recurrent *Clostridium difficile* infection (CDI). Many clinical trials focused on different diseases were in progress. To date, scarce research and long-term follow-up data have been conducted on FMT in children or on the proper guidelines. Our center first performed FMT to treat a 13-month-old boy with severe CDI in 2013. Until February 2018, our center had performed 114 pediatric FMT procedures in 49 subjects.

***AIM***

To investigate the safety of FMT in children.

***METHODS***

A retrospective study was conducted on 49 patients who underwent 114 FMT treatments in our hospital. All FMT processes followed uniform standards. Adverse events (AEs) related to FMT were divided into short-term (48 h post-FMT) and long-term (3 mo). All potential impact factors for AEs, such as gender, age, time of FMT infusion, route of administration, disease type, immune function state and donor relative genetic background, were analyzed as independent factors. The significant independent factors and risk ratio with 95% confidence intervals (CIs) were assessed by multivariate logistic regression analysis.

***RESULTS***

Forty-nine patients (mean age 68.1 mo, range 4 to 193) were recruited. Their average follow-up time after the first FMT was 23.1 mo. The incidence of short-term AEs was 26.32% (30/114). The most common short-term AEs were abdominal pain, diarrhea, fever and vomiting, which were all self-limited and symptom-free within 48 h. Two severe AEs occurred, and one patient died in the fourth week after FMT. All-cause mortality was 2.04%. As independent factors, age (*P =* 0.006) and immune state (*P =* 0.002) had significant effects. Age greater than 72 mo seemed to be correlated with more AEs than age 13 to 36 mo (*P =* 0.04). In multivariate logistic regression analysis, the immune state was an independent risk factor for AE occurrence (*P =* 0.035), and the risk ratio in immunodeficient patients was 3.105 (95%CI: 1.080-8.923).

***CONCLUSION***

Although FMT was proven to be tolerated in children, we need to be more cautious with immunodeficient patients. The effect on children’s long-term health is unpredictable.

**Key words:** Safety; Fecal microbiota transplantation; Pediatrics; Adverse event; Immune system diseases; Age factors

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** A retrospective study was conducted on 49 patients who underwent 114 fecal microbiota transplantation (FMT) treatments in our hospital. The safety of FMT was evaluated by short-term, long-term, and severe adverse events (AEs). The incidence of short-term AEs was 26.32% (30/114). The most common short-term AEs were abdominal pain, diarrhea, fever and vomiting. Age and immune state had significant effects, and the immune state was an independent risk factor for AEs occurrence. The risk ratio in immunodeficient patients was 3.105. Pediatricians need to be more cautious when FMT is applied to immunodeficient patients.

Zhang XY, Li XL, Hu H, Liu HF, Li D, Xiao YM, Wang YZ, Zhang T. Safety of fecal microbiota transplantation in chinese children: a single-center retrospective study. *World J Clin Cases* 2018; In press

**Introduction**

Fecal microbiota transplantation (FMT) is the administration of fecal bacteria liquid from healthy donors to a recipient’s digestive tract. FMT can quickly adjust, restore and rebalance the recipient’s intestinal microbiota, repair the intestinal mucosal barrier, settle the inflammatory response, and regulate the immune system[1,2]. FMT is recommended as a therapeutic method for recurrent *Clostridium difficile* (*C. difficile*) infection (CDI) by various guidelines[3,4]. There is also much clinical research focusing on FMT to treat different diseases, such as inflammatory bowel disease, constipation, irritable bowel syndrome, autism, allergy, metabolic syndrome[1,5,6].

To date, scarce research has been conducted on FMT in children or on the proper guidelines. As safety is uncertain and there is a lack of long-term follow-up data, the pediatricians’ attitude has been relatively conservative. The safety of FMT has been confirmed in adults[7-9]. A clinical trial for 7- to 21-year-old children and young adults with ulcerative colitis (UC) showed that FMT was well tolerated and safe[10].

Our center first performed FMT to treat a 13-month-old boy with severe CDI in 2013[11]. Until February 2018, our center had performed 114 pediatric FMT procedures in 49 subjects. We here retrospectively evaluated the safety of these procedures and analyzed the adverse events (AEs).

**Materials and Methods**

***Study population***

Forty-nine patients who underwent FMT in Shanghai Children’s Hospital from November 2013 to February 2018 were recruited into our retrospective analysis. The pediatric patients underwent FMT included children with the diagnosis of recurrent CDI (with or without inflammatory bowel disease), chronic intractable diarrhea, functional gastrointestinal disorder, metabolic syndrome, [non-alcoholic](javascript:;) [steatohepatitis](javascript:;), severe eczema, systemic juvenile rheumatoid arthritis (sJIA), hemophagocytic lymphohistiocytosis with Epstein-Barr virus (EBV) infection and Okuda syndrome with severe constipation (Table 1). Written informed consent was obtained from parents or legal guardians of all pediatric subjects. This study was approved by the Regional Ethical Review Board in Shanghai Children’s Hospital (2014RY015-E02).

***Criteria of donor***

Donors aged between 18 to 50 without smoking, alcohol, or other bad habits or digestive symptoms were provided from rigorously screened healthy donors from a universal stool bank (OpenBiome)[12]. Eligible donors underwent serological testing for HIV type 1 and 2 antibody (Ab), hepatitis A total Ab, hepatitis B surface antigen (Ag), hepatitis B surface Ab, hepatitis B core Ab (IgM and IgG), hepatitis C Ab, syphilis Ab, CMV IgM, EBV-DNA, h[uman](https://baike.baidu.com/item/Human) parvovirus B19 IgM, TORCH, T-SPOT, hepatic and renal function, blood routine, and lymphatic subgroup analysis. The participants also underwent stool testing with bacterial culture for enteric pathogens (*Escherichia coli* 0157, Salmonella, Shigella, Yersinia, Campylobacter, *Staphylococcus aureus*, *Vibrio parahaemolyticus*, *Vibrio cholerae*), parasitic ovum and parasites; *C. difficile* toxin A/B; fecal Giardia, Cryptosporidium, and *Helicobacter pylori* antigens; and Norovirus and Rotavirus through EIA. The 16s RNA bacteria sequence was tested if it was necessary. Other tests included abdominal ultrasound scan and C13 breath test.

***Bacterial liquid preparation***

Fresh stool from each donor was collected and blended using 200-250 mL sterilized saline per 150 g stool at high speed for 2-3 min. The stool suspension was filtered by 2 layers of medical gauze to remove large particles. Stool filtrate was drawn into 50 mL syringes for [immediate](javascript:void(0);) FMT [use](javascript:void(0);) or collected in 50 mL tubes frozen in -80 °C for further use[13].

***Fecal microbiota transplant procedure***

The bacteria liquid was resuscitated and transferred into the patients’ digestive tract. The route of administration varied and included nasojejunal tube, nasogastric tube and enema. The time of FMT infusion was divided into single infusion (1 d) or multiple infusions (2-3 d continuously). Five millilitre of bacterial liquid for per kilogram weight of the patient was used. The dose was adjusted by the age or weight of patients, and when the patient’s weight was more than 50 kg, the dose for adults was used[14]. The patients fasted for at least 4 h before FMT, and infusion was slowly administered through a tube. After the infusion procedure, patients were asked to keep the same position (＞ 30° semireclining position or hip-up position) for at least 2 h[15].

***Safety evaluation***

AEs were evaluated and assessed according to clinical manifestation, laboratory tests and follow-up period. All AEs were divided into short-term (48 h post-FMT) and long-term (3 mo)[16,17]. The short-term AEs were defined as any untoward medical occurrence that did not exist before FMT or syndrome deterioration in a patient to whom FMT was administered. Short-term AEs could be clinically significant changes from baseline physical exam, laboratory tests, or other diagnostic investigations, complications related to the procedure used to administer FMT, or new events or pre-existing conditions that became aggravated or worsened in severity or frequency within 48 h post-FMT. The potential long-term AEs under our supervision included infection due to unrecognized infectious agents, chronic diseases based on gut microbiota alteration, restriction of growth, and changes in behavior. The intensity and severity of AEs with FMT followed the Common Terminology Criteria for Adverse Events (version 3.0), in which severe AEs (SAEs) were any adverse experience occurring during or after FMT beyond mild or moderate AEs. AEs and SAEs were determined to be related or unrelated[7].

***Data analysis***

IBM SPSS Statistics 20 was used for statistical analysis. The independent factors were analyzed by the Pearson/Fisher *χ2* test or rank sum test, while the between-group variance was determined by Tukey’s HSD test. Values of *P* < 0.05 were considered statistically significant. The significant independent factors and risk ratio with 95% confidence intervals (CIs) were assessed by multivariate logistic regression analysis.

**Results**

***Patient and donor characteristics***

The characteristics of all patients and donors were listed in Table 1. Twenty-seven male and 22 female subjects, with a mean age 68.1 mo (range 4 to 193 mo) were enrolled in this cohort. Their average follow-up time after the first FMT was 23.1 mo. The 49 subjects were divided into two major groups (gastrointestinal disorders and nongastrointestinal disorders). Fifteen patients were diagnosed as immunodeficient (6 primary immunodeficiency and 9 inflammatory bowel disease (IBD) patients with immunosuppressive agent treatment) after FMT. Twenty patients accepted FMT once, while 29 patients had 2-11 rounds of FMT. There were 30 donors (11 of them male), whose mean age was 32.8 years old, including 14 patients’ family members (12 of them were parents and 2 of them were sisters) and 16 volunteers.

***Adverse events***

All short-term AEs were self-limited and symptom-free within 48 h. In total, 38.78% (19/49) of patients had AEs after FMT. Six of them had multiple AEs (2-4), and 10 of 15 immunodeficient patients had AEs. The number of AEs compared with different category was listed in Table 2. The total incidence of short-term AEs was 26.32% (30/114) (Table 3). The most common AEs were abdominal pain (8/114, 7.02%), diarrhea (7/114, 6.14%), fever (6/114, 5.26%) and vomiting (6/114, 5.26%). The incidence of upper gastrointestinal symptoms such as nausea, sore throat and vomiting was 7.89% (9/114). Lower gastrointestinal symptoms such as diarrhea, abdominal pain and mucoid stool were observed in 14.04% (16/114). Other manifestations, such as fever, appetite decrease and chest distress, happened in 7.02% (8/114). In all nasogastric tube ways, 80% (4/5) of AEs were vomiting and the other AEs was appetite decrease with abdominal pain. After enema, 66.7% (4/6) AEs were the changes of stool (3 diarrhea and 1 mucoid stool), which might indicate that the different gastrointestinal symptoms were related to different route of administration. Out of all FMT treatments, severe AEs occurred in 2 cases. One UC case (PUCAI = 45) appeared with 60 ml blood stool 6 h post-FMT. Another UC case (PUCAI = 55) with gastric stricture accompanied by nausea and hematemesis (30 ml) happened 4 h after FMT.

No relevant long-term AEs happened during 3 mo’ follow-up. One primary immunodeficiency patient was treated by FMT for chronic intractable diarrhea. The patient died due to sepsis and liver failure 4 wk after FMT. All-cause mortality was 2.04%.

Comparing either each individual or every FMT, the AE occurrence had no significant difference (**2 test, *P =* 0.252, data not shown). Ten of 15 immunodeficient patients showed AEs, compared with 9 of 34 immune function normal patients, which indicated that immunodeficient patients might have greater risk than others (**2 test, *P =* 0.008, data not shown). All potential AE impact factors, such as gender, age, time of FMT infusion, route of administration, disease type, immune function state and donor relative genetic background, were investigated through the **2 test. As independent factors, only age (rank sum test, *P =* 0.006, data not shown) and immune state (**2 test, *P =* 0.002) had significant effects on AE occurrence (Table 4). Therefore, we divided the patients into different age groups to determine how age affected AEs. The data showed that four age groups had a difference in AE rate (**2 test, *P =* 0.02), and age more than 72 mo was associated with more AEs than age 13 to 36 mo (Tukey’s HSD test between different groups, *P =* 0.04, data not shown). The reason why they had different AE rates might be the bias that older children could give a more accurate description of uncomfortable symptoms. Furthermore, we analyzed age groups and immune states with multivariate logistics regression analysis (Table 3). The results showed that the immune state was an independent risk factor for AE occurrence (*P =* 0.035), and the risk ratio in immunodeficient patients was 3.105 (95% CI: 1.080-8.923).

**Discussion**

This retrospective analysis investigated the safety of FMT in children. We focused on the AEs in the short term and long term in FMT patients from November 2013 to February 2018 in our hospital. The results showed that only a few patients had (transient, self-limited) AEs. During the long-term follow-up, few AEs occurred.

According our data, the immunodeficient patients had more AEs than others, so we need to be more cautious when administering FMT to immunodeficient patients. Most AEs were short-lived, self-limited and manageable. The AEs might have occurred because their condition was more serious. Available research suggests that FMT is safe in different populations, such as immune deficiency, acute graft-versus-host disease, stem cell transplantation and cancer patients[18-23]. Six of our patients who received FMT treatment were finally diagnosed with primary immunodeficiency. All of them were suffering severe, chronic, intractable diarrhea beyond antibiotic control with or without CDI. A definitive diagnosis had not been made before the FMT. The use of FMT aimed to improve their clinical manifestation by balancing the intestinal microbiota. Two of them accepted hematopoietic stem cell transplantation and were cured[24]. Four of them died for reasons unrelated to FMT. One was represented in the previous section. The other three died because of failure to survive with severe diarrhea and septic pyemic shock. Nine IBD patients with immunosuppressive agent treatment, such as glucocorticoid and infliximab, were diagnosed with CDI during the course of their disease. They suffered from diarrhea with mucoid blood stool with or without fever, so FMT was done to treat the CDI and repair the intestinal mucosal barrier. Two severe AEs occurred in active UC patients who had 60 ml blood stool and 30 ml hematemesis, respectively, and others tolerated the FMT well. Blood stool might have been related to the operation process, and hematemesis should be taken as an injury of the gastrointestinal mucosa during the process of inputting the jejunum tube. In the literature, there have been five patients with fatal AEs related to FMT, which were caused by toxic megacolon with sepsis, peritonitis, two cases of fatal aspiration pneumonia and anesthesia death under coloscopy[18,25-28]. Our patients did not have fatal AEs. Both of our severe AE patients were stable, and no more AEs appeared during the next clinical observation.

The effect of FMT on children’s intestinal microbiota and long-term health is still unpredictable due to the microbial liquid from adults. It has been more than 3 years after the first FMT case. Throughout the follow-up, there have been no relevant AEs or special changes in growth or behavior. Another patient died outside of the 3-mo post-FMT period, but this was not considered an SAE. The patient was diagnosed with chronic active EBV infection and died more than 6 mo after FMT due to this infection.

We first performed FMT to treat a 13-mo-old boy with severe CDI in 2013[11]. The data from our group show that although the general age of the patients was young, they tolerated the FMT treatment with good safety outcomes. The use of FMT on immunodeficient patient needs to be more cautious. The complete FMT follow-up pediatric cohort was set up for further study of FMT in children. There were also some limitations to our study. Our retrospective study lacked the advantage of a randomized control trial. The bias of AEs by subjective description was inevitable. The number of cases was limited; thus, bias also existed.

**ARTICLE HIGHLIGHTS**

***Research background***

Fecal microbiota transplantation (FMT) is the administration of fecal bacteria liquid from healthy donors to a recipient’s digestive tract, which is recommended as a therapeutic method for recurrent *Clostridium difficile* infection (CDI). Many clinical trials focused on different diseases were in progress. To date, scarce research and long-term follow-up data have been conducted on FMT in children or on the proper guidelines. Our center first performed FMT to treat a 13-month-old boy with severe CDI in 2013. Until February 2018, our center had performed 114 pediatric FMT procedures in 49 subjects. We here retrospectively evaluated the safety of these procedures and analyzed the adverse events (AEs).

***Research motivation***

To investigate the safety of FMT in children.

***Research objectives***

Evaluate the adverse events occurred during and after the procedure of FMT.

***Research methods***

Forty-nine patients in Shanghai Children’s Hospital from November 2013 to February 2018 were recruited into our retrospective analysis. All FMT processes followed uniform standards. AEs related to FMT were divided into short-term (48 h post-FMT) and long-term (3 mo). All potential impact factors for AEs, such as gender, age, time of FMT infusion, route of administration, disease type, immune function state and donor relative genetic background, were analyzed as independent factors. The significant independent factors and risk ratio with 95% confidence intervals (CIs) were assessed by multivariate logistic regression analysis.

***Research results***

Forty-nine patients (mean age 68.1 mo, range 4 to 193) were recruited. Their average follow-up time after the first FMT was 23.1 mo. The incidence of short-term AEs was 26.32% (30/114). The most common short-term AEs were abdominal pain, diarrhea, fever and vomiting, which were all self-limited and symptom-free within 48 h. Two severe AEs occurred, and one patient died in the fourth week after FMT. All-cause mortality was 2.04%. As independent factors, age (*P =* 0.006) and immune state (*P =* 0.002) had significant effects. Age greater than 72 mo seemed to be correlated with more AEs than age 13 to 36 mo (*P =* 0.04). In multivariate logistic regression analysis, the immune state was an independent risk factor for AE occurrence (*P =* 0.035), and the risk ratio in immunodeficient patients was 3.105 (95%CI: 1.080-8.923).

***Research conclusions***

FMT was proven to be tolerated and safe in children. But we need to be more cautious with immunodeficient patients. The effect on children’s long-term health is unpredictable.

***Research perspectives***

FMT was well tolerated and safe in children, while more data for immunodeficient pediatric patients was required.

**Acknowledgments**

The authors would like to thank all the staff of Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children’s Hospital who provided the clinical help and support.

**References**

1 **Kelly CR**, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. *Gastroenterology* 2015; **149**: 223-237 [PMID: 25982290 DOI: 10.1053/j.gastro.2015.05.008]

2 **Weingarden AR**, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. *Gut Microbes* 2017; **8**: 238-252 [PMID: 28609251 DOI: 10.1080/19490976.2017.1290757]

3 **Surawicz CM**, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *Am J Gastroenterol* 2013; **108**: 478-498; quiz 499 [PMID: 23439232 DOI: 10.1038/ajg.2013.4]

4 **Debast SB**, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. *Clin Microbiol Infect* 2014; **20** Suppl 2: 1-26 [PMID: 24118601 DOI: 10.1111/1469-0691.12418]

5 **Chen X**, Devaraj S. Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes. *Curr Diab Rep* 2018; **18**: 129 [PMID: 30338410 DOI: 10.1007/s11892-018-1104-3]

6 **Simrén M**, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 589-605 [PMID: 29930260 DOI: 10.1038/s41575-018-0034-5]

7 **Wang S**, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. *PLoS One* 2016; **11**: e0161174 [PMID: 27529553 DOI: 10.1371/journal.pone.0161174]

8 **Baxter M**, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. *J Hosp Infect* 2016; **92**: 117-127 [PMID: 26803556 DOI: 10.1016/j.jhin.2015.10.024]

9 **Li YT**, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. *Aliment Pharmacol Ther* 2016; **43**: 445-457 [PMID: 26662643 DOI: 10.1111/apt.13492]

10 **Kunde S**, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2013; **56**: 597-601 [PMID: 23542823 DOI: 10.1097/MPG.0b013e318292fa0d]

11 **Wang J**, Xiao Y, Lin K, Song F, Ge T, Zhang T. Pediatric severe pseudomembranous enteritis treated with fecal microbiota transplantation in a 13-month-old infant. *Biomed Rep* 2015; **3**: 173-175 [PMID: 25798243 DOI: 10.3892/br.2014.403]

12 **Ling K,** Koelsch E, Dubois N, O'Brien K, Stoltzner Z, Panchal P, Amaratunga K, Kassam Z, Osman M. Prospective Laboratory Evaluation of Fecal Microbiota Transplantation Donors: Results From an International Public Stool Bank. *Open Forum Infect Dis* 2016; **3**(suppl\_1) [DOI: 10.1093/ofid/ofw172.1671]

13 **Suskind DL**, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, Miller SI. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. *Inflamm Bowel Dis* 2015; **21**: 556-563 [PMID: 25647155 DOI: 10.1097/MIB.0000000000000307]

14 **Rossen NG**, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol* 2015; **21**: 5359-5371 [PMID: 25954111 DOI: 10.3748/wjg.v21.i17.5359]

15 **Zhang F**, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. *Protein Cell* 2018; **9**: 462-473 [PMID: 29691757 DOI: 10.1007/s13238-018-0541-8]

16 **Choi HH**, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. *Clin Endosc* 2016; **49**: 257-265 [PMID: 26956193 DOI: 10.5946/ce.2015.117]

17 **Li SS**, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. *Science* 2016; **352**: 586-589 [PMID: 27126044 DOI: 10.1126/science.aad8852]

18 **Kelly CR**, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. *Am J Gastroenterol* 2014; **109**: 1065-1071 [PMID: 24890442 DOI: 10.1038/ajg.2014.133]

19 **Kakihana K**. Fecal microbiota transplantation for acute graft-versus-host disease of the gut. *Rinsho Ketsueki* 2017; **58**: 499-505 [PMID: 28592766 DOI: 10.11406/rinketsu.58.499]

20 **Webb BJ**, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. *Transpl Infect Dis* 2016; **18**: 628-633 [PMID: 27214585 DOI: 10.1111/tid.12550]

21 **Neemann K**, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. *Transpl Infect Dis* 2012; **14**: E161-E165 [PMID: 23121625 DOI: 10.1111/tid.12017]

22 **Mittal C**, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. *Bone Marrow Transplant* 2015; **50**: 1010 [PMID: 25893454 DOI: 10.1038/bmt.2015.85]

23 **Hefazi M**, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. *Mayo Clin Proc* 2017; **92**: 1617-1624 [PMID: 29101931 DOI: 10.1016/j.mayocp.2017.08.016]

24 **Ge T**, Wang Y, Che Y, Xiao Y, Zhang T. Atypical Late-Onset Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome with Intractable Diarrhea: A Case Report. *Front Pediatr* 2017; **5**: 267 [PMID: 29312905 DOI: 10.3389/fped.2017.00267]

25 **Baxter M**, Ahmad T, Colville A, Sheridan R. Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant. *Clin Infect Dis* 2015; **61**: 136-137 [PMID: 25805303 DOI: 10.1093/cid/civ247]

26 **Högenauer C**, Kump PK, Krause R. Tempered enthusiasm for fecal transplantation? *Clin Infect Dis* 2014; **59**: 1348-1349 [PMID: 25034424 DOI: 10.1093/cid/ciu567]

27 **Aas J**, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis* 2003; **36**: 580-585 [PMID: 12594638 DOI: 10.1086/367657]

28 **Goldenberg SD**, Batra R, Beales I, Digby-Bell JL, Irving PM, Kellingray L, Narbad A, Franslem-Elumogo N. Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. *Infect Dis Ther* 2018; **7**: 71-86 [PMID: 29450831 DOI: 10.1007/s40121-018-0189-y]

**P-Reviewer:** Amedei A, Kenar T, Lin J **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Patient and donor characteristics**

|  |  |  |
| --- | --- | --- |
|  | **Items** | **Results** |
| Patients | Total number of study patients | 49 |
| Gender, male *n* (%) | 27 (55.1) |
| Age [mean ± SD (range), mo] | 68.16 ± 53.09 (4-193) |
| Follow-up duration [mean ± SD (range), mo] | 23.14 ± 15.32 (1-55) |
| Disease type |  |
| Gastrointestinal disorder |  |
| CDI1 | 33 |
| Chronic intractable diarrhea (without CD evidence)2 | 6 |
| Functional gastrointestinal disorder | 1 |
| Nongastrointestinal disorder |  |
| Metabolic syndrome | 1 |
| NASH | 2 |
| Eczema | 2 |
| Others3 | 4 |
| Patients with single *vs* multiple FMTs |  |
| Single | 20 |
| Multiple (range of FMT rounds) | 29 (2-11 rounds) |
| Immunodeficiency | 15 |
| Donors | Total number | 30 |
| Gender, male *n* (%) | 11 (36.7) |
| Age, [mean ± SD (range), yr] | 32.77 ± 8.266 (2-49) |
| Relative genetic background, relative *n* (%) | 46.7 (14) |

1CDI is *Clostridium difficile* infection in 2 primary immunodeficiency patients (VEO-IBD with *IL10Ra* gene mutation and IPEX with *FOXP3* gene mutation), 9 IBD patients on immunosuppressive agents and 18 recurrent CDI patients; 2Chronic intractable diarrhea without CD evidence in 4 primary immunodeficiency patients (one DNA ligase IV syndrome with *LIG4* gene mutation and three undetermined immunodeficiency) and 2 cases of antibiotic-associated diarrhea; 3other diseases include one systemic juvenile rheumatoid arthritis, two hemophagocytic lymphohistiocytosis with Epstein-Barr virus infection and one Okuda syndrome with severe constipation. NASH: [non-alcoholic](javascript:;) [steatohepatitis](javascript:;); FMT: Fecal microbiota transplantation; IBD: inflammatory bowel disease.

**Table 2 Different category of fecal microbiota transplantation in all rounds**

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** | **Sub-item** | **Number of AEs** | **Total rounds of FMT** |
| Age group | 0-12 | 1 | 12 |
|  | 13-36 | 4 | 30 |
|  | 37-72 | 5 | 22 |
|  | 73 | 20 | 50 |
| Route of administration | Nasogastric tube | 5 | 20 |
|  | Nasal jejunal tube | 19 | 58 |
|  | Enema | 6 | 36 |
| Number of FMT infusions | Single | 23 | 88 |
|  | Multiple | 7 | 26 |
| Immune state | Immune deficiency | 16 | 35 |
|  | Normal immune function | 14 | 79 |

AEs: Adverse events; FMT: Fecal microbiota transplantation.

|  |  |  |  |
| --- | --- | --- | --- |
| **Upper gastrointestinal symptoms** | **Lower gastrointestinal symptoms** | **Other manifestations** | **Severe adverse events** |
| Sore throat  1 (0.88) | Diarrhea  7 (6.14) | Fever  6 (5.26) | Hematemesis  1 (0.88) |
| Vomit  6 (5.26) | Abdominal pain  8 (7.02) | Appetite decrease  1 (0.88) | Hematochezia  1 (0.88) |
| Nausea  2 (1.75) | Mucoid stool  1 (0.88) | Chest distress  1 (0.88) |  |

**Table 3 Short-term adverse events *n* (%)**

**Table 4 Potential impact factors on fecal microbiota transplantation adverse eventoccurrence**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Item** | **Sub-item** | ****2** | ***P* value** | **Wald test** | ***P* value** |
| Gender | Male | 0.456 | 0.499 |  |  |
|  | Female |
| Age group (m) | 0-12 | 9.583 | 0.02 | 4.413 | 0.22 |
| 13-36 |
| 37-72 |
| 73 |
| Number of Fecal microbiota transplantation infusions | Single | 0.006 | 0.936 |  |  |
| Multiple |
| Route of administration | Nasogastric tube | 2.988 | 0.224 |  |  |
| Nasal jejunal tube |
| Enema |
| Disease type | Gastrointestinal disorder | 2.182 | 0.14 |  |  |
| Nongastrointestinal disorder |
| Immune state | Immune deficiency | 9.801 | 0.002 | 4.425 | 0.035 |
| Normal immune function |
| Donor genetic background | Relative | 1.119 | 0.29 |  |  |
| Nonrelative |